Journal of Viral Hepatitis

• Therapeutic Vaccination for Chronic Hepatitis B This review examined the current evidence for the efficacy and safety of therapeutic vaccines compared to no treatment, placebo or standard care in the treatment of chronic hepatitis B.
  Journal of Viral Hepatitis, July 2019
• Diabetes and Risk of HCC and Mortality in Chronic HBV This study investigated the impact of diabetes mellitus on the development and prognosis of hepatocellular carcinoma in individuals with chronic hepatitis B virus infection.
  Journal of Viral Hepatitis, July 2019
• Recurrence of HCC Following LDV/SOF Treatment in Chronic HCV How does treatment with ledipasvir/sofosbuvir impact the risk of a new occurrence and/or recurrence of hepatocellular carcinoma in patients with HCV?
  Journal of Viral Hepatitis, June 2019
• OBV/PTV/r +/- DSV +/- RBV in HCV With Diverse Comorbidities Does real-world evidence confirm the effectiveness of OBV/PTV/r +/- DSV +/- RBV in patients with HCV GT1 or GT4, and how do comorbidities or comedications impact outcomes?
  Journal of Viral Hepatitis, June 2019
• Ruzasvir Plus Uprifosbuvir for 12 Weeks in Chronic HCV This study indicates that the combination of ruzasvir 60 mg plus uprifosbuvir 450 mg once daily for 12 weeks is well tolerated overall, but effective only for certain HCV genotypes.
  Journal of Viral Hepatitis, June 2019
• Response to HCV Treatment by PWID in Needle & Syringe Program This study aimed to assess whether people who actively inject drugs can be recruited and treated successfully through a community needle and syringe program.
  Journal of Viral Hepatitis, May 2019
• Awareness of Chronic Viral Hepatitis in the United States How cognizant are US individuals of their status regarding HBV or HCV infection? How does infection awareness differ by demographics?
  Journal of Viral Hepatitis, May 2019
• HCV Genotype 3 Associated With the Development of HCC This study compared the rate of HCC development and disease progression among patients with chronic hepatitis C who have genotype 3 HCV compared to those of patients infected with other HCV genotypes.
  Journal of Viral Hepatitis, May 2019
• Effectiveness, Acceptability of Community-Based HCV Treatment What is the clinical effectiveness, acceptability and cost effectiveness of community-based models of care for treating chronic HCV?
  Journal of Viral Hepatitis, April 2019
• Neuropsychiatric Symptoms in Hepatitis C Patients How do neuropsychiatric symptoms differ among those with hepatitis C versus other manifestations of hepatitis, and what insights might these differences provide regarding their etiology?
  Journal of Viral Hepatitis, April 2019
• Improved Liver Transplant Waitlist Mortality With DAAs Did introduction of sofosbuvir increase the survival of patients awaiting liver transplant?
  Journal of Viral Hepatitis, April 2019
• Glecaprevir/Pibrentasvir in Chronic HCV Genotype 3 Infection Is glecaprevir/pibrentasvir effective in patients with chronic HCV genotype 3 infection and compensated cirrhosis?
  Journal of Viral Hepatitis, April 2019
• Viral Load and Efficacy of Elbasvir/Grazoprevir for HCV More patients with HCV genotype 1a infection may be able to receive 12 rather than 16 weeks of elbasvir/grazoprevir after baseline resistance testing.
  Journal of Viral Hepatitis, March 2019
• Antivirals for Blocking Mother-to-Child Transmission of HBV Is lamivudine as effective as tenofovir disoproxil fumarate for preventing mother-to-child transmission of HBV?
  Journal of Viral Hepatitis, March 2019
• SOF/DCV Treatment for Children and Adolescents With HCV Is combined sofosbuvir/daclatasvir effective and safe for treating HCV genotype 4-infected children over 8 years of age?
  Journal of Viral Hepatitis, March 2019
• Liver Transplant Listing for HCV-associated Cirrhosis and HCC How has the availability of direct-acting antiviral therapy impacted liver transplantation indications and waiting list outcomes in patients with chronic hepatitis C?
  Journal of Viral Hepatitis, March 2019
• Estimating Liver Fibrosis in HCV: Serum Markers vs TE This study compared the diagnostic accuracy of a panel of noncommercial serum scores to transient elastography for determining the extent of hepatic fibrosis in HCV patients on DAA-based therapy.
  Journal of Viral Hepatitis, February 2019
• Improving Hepatitis C DAA Access and Uptake How does treatment with DAAs alter the social and individual experience of living with hepatitis C? This commentary highlights the need for an individual focus for outcome measures.
  Journal of Viral Hepatitis, February 2019
• Current Therapies and Viral and Immune Responses in HBV This review summarizes current and future directions for therapeutic options for chronic HBV infection. Is a functional cure for HBV within sight?
  Journal of Viral Hepatitis, February 2019
• Opportunistic Infections After DAAs in HIV/HCV-Coinfection How prevalent is the occurrence of severe immunodepression-related infections after starting interferon-free DAA combinations in HIV/HCV-coinfected patients?
  Journal of Viral Hepatitis, February 2019